{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:41:27Z","timestamp":1774050087982,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Pfizer, S.L.U."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1277-1","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T13:30:54Z","timestamp":1490794254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study"],"prefix":"10.1186","volume":"19","author":[{"name":"on behalf of the MAAPS study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Queiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Montilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"C\u00e1bez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"issue":"3","key":"1277_CR1","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314\u201321.","journal-title":"J Autoimmun"},{"issue":"10","key":"1277_CR2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/art.24608","volume":"61","author":"G Ibrahim","year":"2009","unstructured":"Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61(10):1373\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6 Suppl 43","key":"1277_CR3","first-page":"S-7","volume":"24","author":"A Kavanaugh","year":"2006","unstructured":"Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S-7.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1277_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1277_CR5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62(7):965\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1277_CR6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3899\/jrheum.150805","volume":"43","author":"FM Perrotta","year":"2016","unstructured":"Perrotta FM, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-alpha drugs. J Rheumatol. 2016;43(2):350\u20135.","journal-title":"J Rheumatol"},{"issue":"6","key":"1277_CR7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acr.22529","volume":"67","author":"A Haddad","year":"2015","unstructured":"Haddad A, Thavaneswaran A, Ruiz-Arruza I, Pellett F, Chandran V, Cook RJ, et al. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67(6):842\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"1277_CR8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3899\/jrheum.151404","volume":"43","author":"E Lubrano","year":"2016","unstructured":"Lubrano E, Parsons WJ, Perrotta FM. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2016;43(5):918\u201323.","journal-title":"J Rheumatol"},{"issue":"7","key":"1277_CR9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2011-200387","volume":"71","author":"V Strand","year":"2012","unstructured":"Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71(7):1143\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1277_CR10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10067-006-0298-y","volume":"26","author":"P Borman","year":"2007","unstructured":"Borman P, Toy GG, Babaoglu S, Bodur H, Ciliz D, Alli N. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol. 2007;26(3):330\u20134.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1277_CR11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr.20104","volume":"62","author":"AA Saad","year":"2010","unstructured":"Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken). 2010;62(3):345\u201353.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"1277_CR12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1277_CR13","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1277_CR14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/art.24562","volume":"61","author":"V Chandran","year":"2009","unstructured":"Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum. 2009;61(9):1235\u201342.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1277_CR15","first-page":"886","volume":"22","author":"MG Blackmore","year":"1995","unstructured":"Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol. 1995;22(5):886\u201393.","journal-title":"J Rheumatol"},{"issue":"12","key":"1277_CR16","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"7","key":"1277_CR17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Cook R, Lee KA, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010;62(7):970\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1277_CR18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","volume":"73","author":"E Theander","year":"2014","unstructured":"Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"1-2","key":"1277_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12026-014-8595-z","volume":"61","author":"L Costa","year":"2015","unstructured":"Costa L, Caso F, Ramonda R, Del PA, Cantarini L, Darda MA, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. 2015;61(1-2):147\u201353.","journal-title":"Immunol Res"},{"issue":"1","key":"1277_CR20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","volume":"65","author":"MN Minno Di","year":"2013","unstructured":"Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken). 2013;65(1):141\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"1277_CR21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"1277_CR22","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1002\/ddr.21197","volume":"75","author":"MS Chimenti","year":"2014","unstructured":"Chimenti MS, Triggianese P, Conigliaro P, Santoro M, Lucchetti R, Perricone R. Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity. Drug Dev Res. 2014;75 Suppl 1:S57\u20139.","journal-title":"Drug Dev Res"},{"issue":"5","key":"1277_CR23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.berh.2014.10.009","volume":"28","author":"P Jacques","year":"2014","unstructured":"Jacques P, McGonagle D. The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol. 2014;28(5):703\u201310.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"1277_CR24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.rdc.2015.07.006","volume":"41","author":"JL Barnas","year":"2015","unstructured":"Barnas JL, Ritchlin CT. Etiology and pathogenesis of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):643\u201363.","journal-title":"Rheum Dis Clin North Am"},{"key":"1277_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O FitzGerald","year":"2015","unstructured":"FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17:115.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1277_CR26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/1346-8138.13157","volume":"43","author":"JL Lopez-Estebaranz","year":"2016","unstructured":"Lopez-Estebaranz JL, Sanchez-Carazo JL, Sulleiro S. Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: results from the ARIZONA study. J Dermatol. 2016;43(4):395\u2013401.","journal-title":"J Dermatol"},{"issue":"Suppl 1","key":"1277_CR27","first-page":"52","volume":"59","author":"L Punzi","year":"2007","unstructured":"Punzi L, Podswiadek M, Oliviero F, Lonigro A, Modesti V, Ramonda R, et al. Laboratory findings in psoriatic arthritis. Reumatismo. 2007;59 Suppl 1:52\u20135.","journal-title":"Reumatismo"},{"issue":"4","key":"1277_CR28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/rheumatology\/36.4.409","volume":"36","author":"CE Griffiths","year":"1997","unstructured":"Griffiths CE. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol. 1997;36(4):409\u201310.","journal-title":"Br J Rheumatol"},{"issue":"5","key":"1277_CR29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1277_CR30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jbspin.2015.06.018","volume":"83","author":"S Talli","year":"2016","unstructured":"Talli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Canete JD, et al. Patient global assessment in psoriatic arthritis\u2014what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine. 2016;83(3):335\u201340.","journal-title":"Joint Bone Spine"},{"key":"1277_CR31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/TCRM.S101619","volume":"12","author":"F Salaffi","year":"2016","unstructured":"Salaffi F, Di CM, Carotti M, Farah S, Gutierrez M. The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version. Ther Clin Risk Manag. 2016;12:631\u201342.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"1277_CR32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/ar4414","volume":"15","author":"DJ Veale","year":"2013","unstructured":"Veale DJ. Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Res Ther. 2013;15(6):224.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1277_CR33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3899\/jrheum.110763","volume":"39","author":"S Iervolino","year":"2012","unstructured":"Iervolino S, Di Minno MN, Peluso R, Lofrano M, Russolillo A, Di MG, et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-alpha blockers. J Rheumatol. 2012;39(3):568\u201373.","journal-title":"J Rheumatol"},{"issue":"7","key":"1277_CR34","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264\u201372.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1277_CR35","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1277_CR36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3899\/jrheum.151290","volume":"43","author":"B Combe","year":"2016","unstructured":"Combe B, Behrens F, McHugh N, Brock F, Kerkmann U, Kola B, et al. Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J Rheumatol. 2016;43(6):1063\u20137.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1277-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T13:46:01Z","timestamp":1498398361000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1277-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,29]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1277-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,29]]},"article-number":"72"}}